Metformina + Sitagliptina Zentiva K.S. (Metformin Hydrochloride, Sitagliptin)

Metformin reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Sitagliptin blocks the enzyme DPP‑4, which increases levels of the incretin hormones GLP‑1 and GIP. These hormones stimulate insulin release in a glucose‑dependent manner and suppress glucagon, together enhancing overall glucose regulation.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

The safety of this combination in pregnancy has not been fully established, and it should only be used if the potential benefits outweigh the risks. Breastfeeding mothers should consult their physician, as metformin is excreted in breast milk while data on sitagliptin are limited.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with metformin alone, the addition of sitagliptin provides greater HbA1c reduction and better post‑prandial glucose control. Unlike sulfonylureas, it carries a lower intrinsic risk of hypoglycemia, and unlike GLP‑1 receptor agonists, it is administered orally rather than by injection.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

The medication is taken orally, usually once daily with or after a meal to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious adverse events include lactic acidosis, which is rare but life‑threatening, and severe hypoglycemia when combined with insulin or sulfonylureas. Pancreatitis and rare severe skin reactions have also been reported, so patients should seek immediate medical attention if symptoms arise.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, or a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.